Clinical Trial

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).
Protocol Amendment History 3 changes
notable Trial sites expanded: 3 -> 8 locations 2026-07-17
critical Recruitment opened 2026-06-16
notable Trial sites expanded: 0 -> 3 locations 2026-06-16
Trial Details
NCT Number NCT07549698
Lead Sponsor CRISPR Therapeutics AG
Conditions Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
Enrollment 60 participants
Start Date 2026-06
Primary Completion 2033-12 (estimated)
Study Completion 2033-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-22